中关村(000931) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net profit of approximately 35 million to 40 million yuan for the first half of 2024, representing a year-on-year increase of 35.86% to 55.27% compared to 25.76 million yuan in the same period last year[6] - The net profit after deducting non-recurring gains and losses is expected to be between 25 million and 30 million yuan, with a year-on-year growth of 30.07% to 56.08% compared to 19.22 million yuan last year[6] - Basic earnings per share are projected to be approximately 0.0465 yuan to 0.0531 yuan, up from 0.0342 yuan per share in the same period last year[6] Business Growth - The increase in net profit is primarily attributed to the continued growth of the company's core biopharmaceutical business, with revenue and net profit both increasing[8] - All business segments of the company have shown year-on-year revenue growth, indicating normal operations across various production and business activities[8] Financial Reporting - The financial data presented is preliminary and has not been reviewed by the accounting firm[7] - The specific financial data for the first half of 2024 will be disclosed in the company's half-year report scheduled for August 28, 2024[1]